Citigroup
VIR icon

Citigroup’s Vir Biotechnology VIR Stock Holding History

Citigroup’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$510K Buy
+50,000
New +$476K ﹤0.01% 3892
2025
Q1 		– Sell
-38,700
Closed -$284K – 5997
2024
Q4 		$284K Buy
+38,700
New +$305K ﹤0.01% 4183
2023
Q1 		– Sell
-29,900
Closed -$757K – 5889
2022
Q4 		$757K Buy
+29,900
New +$733K ﹤0.01% 2867

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citigroup's VIR Position: Q2 2026 in Review

Citigroup reduced its Vir Biotechnology (VIR) stake by 15% in Q2 2026, selling an estimated $359K and leaving 218,419 shares worth $2.23M. The position accounts for ﹤0.01% of the portfolio, ranked #2852.

Citigroup first reported a position in VIR in Q4 2019 and has held it in 27 quarters since. The position peaked at $11.4M in Q1 2024. 238 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Citigroup held 218,419 shares of Vir Biotechnology worth $2.23M as of Q2 2026.
  • Citigroup sold 37,721 Vir Biotechnology shares in Q2 2026, an estimated $359K.
  • Vir Biotechnology made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2852 holding.
  • Citigroup first reported a position in Vir Biotechnology in Q4 2019 and has held it in 27 quarters since.
  • Citigroup's Vir Biotechnology position peaked at $11.4M in Q1 2024.
  • 238 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.